- Headquarters: Massachusetts
- Founded: 2009
- corbuspharma.com
NORWOOD, Mass. (AP) _ Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $7.5 million in its first quarter.
The Norwood, Massachusetts-based company said it had a loss of 16 cents per share.
The drug developer posted revenue of $1.3 million in the period.
Corbus Pharmaceuticals shares have fallen 27 percent since the beginning of the year. The stock has more than doubled in the last 12 months.
********
Description
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Key stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -2083.70% | -1046.27% |
| Operating margin | -2082.17% | -1045.56% |
| EBITD margin | - | -1040.97% |
| Return on average assets | -61.51% | -130.02% |
| Return on average equity | -72.11% | -223.40% |
| Employees | 25 |
No comments:
Post a Comment